Assessing product bioequivalence for extended-release formulations and drugs with long half-lives-Reference-Cited by-同舟云学术

Assessing product bioequivalence for extended-release formulations and drugs with long half-lives

Published:2012-03-13 Issue: Volume:35 Page:3-9
ISSN:0140-7783
Container-title:Journal of Veterinary Pharmacology and Therapeutics
language:en
Short-container-title:

Author:

GEHRING R.,MARTINEZ M.

Publisher

Wiley

Subject

General Veterinary,Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2885.2012.01372.x/fullpdf

Reference9 articles.

1. Bioequivalence study of two different tablet formulations of donepezil using truncated areas under the curve. A single-center, single-dose, randomized, open-label, 2-way crossover study under fasting conditions;Almeida;Arzneimittel-Forschung,2010

2. Do regulatory bioequivalence requirements adequately reflect the therapeutic equivalence of modified-release drug products?;Endrenyi;Journal of Pharmacy & Pharmaceutical Sciences,2010

3. Estimation of absolute oral bioavailability of moxidectin in dogs using a semi-simultaneous method: influence of lipid co-administration;Lallemand;Journal of Veterinary Pharmacology & Therapeutics,2007

4. Bioequivalence testing by statistical shape analysis;Pereira;Journal of Pharmacokinetics and Pharmacodynamics,2007

5. Measurement of zeranol in plasma from three blood vessels in steers implanted with zeranol;Pusateri;Journal of Animal Science,1993

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of Pharmacokinetics and Safety with Bioequivalence of Ibuprofen Sustained-Release Capsules of Two Formulations, in Chinese Healthy Volunteers: Bioequivalence Study;Drug Design, Development and Therapy;2023-06

2. Population pharmacokinetics/pharmacodynamics modelling of enrofloxacin for the three major trout pathogens Aeromonas salmonicida, Flavobacterium psychrophilum and Yersinia ruckeri;Aquaculture;2021-12

3. Bioavailability and Bioequivalence * *Disclaimer: The chapter reflects the views of the authors and should not be construed to represent the views or policies of the Food and Drug Administration (FDA). No official endorsement by the FDA is intended or should be inferred.;Developing Solid Oral Dosage Forms;2017

4. Partial Area Under the Curve: An Additional Pharmacokinetic Metric for Bioavailability and Bioequivalence Assessments;FDA Bioequivalence Standards;2014

5. Bioequivalence accomplishments, ongoing initiatives, and remaining challenges;Journal of Veterinary Pharmacology and Therapeutics;2013-07-11